ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Systematic Review

Better survival of patients with oligo- compared with polymetastatic cancers:  a systematic review and meta-analysis of 173 studies

[version 1; peer review: 1 approved with reservations]
PUBLISHED 27 May 2021
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the Oncology gateway.

Abstract

Background: The modern concept of oligometastatic (OM) state has been initially developed to describe patients with a low burden of disease and with a potential for cure with local ablative treatments. We systematically assessed the risk of death and relapse of oligometastatic (OM) cancers compared to cancers with more diffuse metastatic spread, through a meta-analysis of published data. 
Methods: PubMed, the Cochrane Library, and EMBASE were searched for studies reporting prognosis of patients with OM solid tumors. Risk of death and relapse were extracted and pooled to provide an adjusted hazard ratio with a 95% confidence interval (HR 95%CI).  The primary outcome of the study refers to overall mortality in OM vs. polymetastatic (PM) patients. 
Results. Mortality and relapse associated with OM state in patients with cancer were evaluated among 104,234 participants (n=173 studies). Progression-free survival was better in patients with OM disease (hazard ratio [HR] = 0.62, 95% CI 0.57–0.68; P <.001; n=69 studies). Also, OM cancers were associated with a better OS (HR = 0.65, 95% CI 0.62-0.68; P<.01; n=161 studies). In colorectal (CRC), breast, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) the reduction in the risk of death for OM patients were 35, 38, 30 and 42%, respectively. 
Conclusions. Patients with oligometastases have a significantly better prognosis than those with more widespread stage IV tumors. We suggest that a treatment strategy that involves bot the primary and the metastases should be identified at the time of diagnosis.

Keywords

cancer, oligometastases, survival, review, meta-analysis, tumours

Introduction

The vast majority of metastatic solid tumors are incurable, and despite the evolution of treatments, patients ultimately die because of their disease. The modern concept of oligometastatic (OM) state was initially developed in 19951 to describe patients with a low burden of disease (e.g. one to five metastases) with a potential for cure with local ablative treatments. This assumption also relies on the hypothesis that metastatic spread follows a hierarchical pattern in time and number of localizations.2 In some circumstances, the 8th Tumor Node Metastasis (TNM) staging system distinguishes between patients with a single metastasis and those with multiple such metastases. Large consensus on the definition and management of OM patients is currently lacking. Recently, advances in imaging and local ablative therapies have permitted the treatment of these patients with additional locoregional treatment in addition to systemic therapies, and some patients may be cured and attain long term survival.3 This scenario has been best elucidated in prostate, kidney, lung and melanomas.4,5 In these settings oligometastatic cancers may be treated in oligoprogressive sites continuing systemic therapy that control the remaining disease. Also, oligometastatic tumors at presentation can receive local treatments on the primary tumor and on any single oligometastases. In the SABR-COMET randomized study median overall survival (OS) was 28 months (95% CI 19-33) in the control group versus 41 months (26-not reached) in the stereotactic body radiotherapy to all metastases group (hazard ratio 0.57, 95% CI 0.30-1.10; P = .09).6

The aim of this systematic review and meta-analysis was to investigate and establish the prognostic survival of OM compared to non-OM solid tumors. In particular, we evaluated if patients with oligometastatic solid tumors do better than patients with non-oligometastatic tumors defined as tumors with up to three to five metastatic sites.

Methods

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

Search strategy and inclusion criteria

A comprehensive search was performed with the following terms: (advanced or metastatic or recurrent or relapsed or synchronous or metachronous) and (site or oligo* or “oligometastastic” or oligorecurrence or oligoprogression or single or multiple or 1-3 or >3 or >4 or >5 or 1-2 or 1-3 or 1-5 or number) and (synchronous or metachronous or metastases or relapse or recurrence or progression) and (tumor or tumour or cancer or carcinoma or melanoma or sarcoma) and (“hazard ratio”) and (cox or multivariate or multivariable) and survival. We searched PubMed, the Cochrane Library and EMBASE for studies eligible for this meta-analysis published from inception up to October 30th, 2020. To be eligible, studies needed to have evaluated survival of patients with metastatic cancers regardless of line of therapy and to provide data of outcome according to the number of OM sites used by each author. Studies were excluded if they enrolled less than 10 patients, pediatric subjects, and hematological diseases. Commonly we define polymetastatic cancer as any disease with more than three to five metastases. Studies were searched and screened independently by three authors (FP, MG and GT).

Quality of studies and endpoints

The primary endpoint was overall survival (OS) and the secondary endpoint was progression-free survival (PFS). Quality assessment of the included studies was performed using the Newcastle-Ottawa Scale (NOS) for observational or retrospective studies (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).

Data extraction and statistical analysis

The extracted data (from six reviewers) included the type of study, number of patients, cancer type, median age of included patients, performance status 0-1 (rate), treatment received, timing of oligometastases (synchronous or metachronous), number of OM sites used for comparison, and median follow up. Hazard ratios (HR) for OS and PFS with their 95% CIs, were extracted preferentially from multivariate analyses where available. The heterogeneity in the included studies was evaluated by the Chi-square-based Q-test and I2 (I2 = 0% to 25%, no heterogeneity; I2 = 25% to 50%, moderate heterogeneity; I2 = 50% to 75%, high heterogeneity; I2 = 75% to 100%, extreme heterogeneity). When I2 was larger than 50%, a random effects model was used; otherwise, the fixed effects model was used. Sensitivity analyses for OS were performed according to type of cancer, timing and number of oligometastases to find the potential heterogeneity among the included studies. If the number of studies was less than or equal to one, we did not carry out the subgroup analysis. The possibility of publication bias was explored by the Egger's and Begg's tests and Trim and Fill method.7,8 Begg's test explores bias with a funnel plot, conversely Egger's test is a linear regression of the effect estimates (OS) on their standard errors weighted by their inverse variance. The trim-and-fill method aims at estimating potentially missing studies due to publication bias in the funnel plot and adjusting the overall effect estimate. All analyses were performed using RevMan v.3 software.9

Results

Among the publications retrieved using electronic search (n = 7510), 173 studies were eligible for meta-analysis, for a total of 104,234 patients10 (Figure 1). Baseline characteristics of the included studies and treatments received are presented in Table 1.

f8157814-93df-4685-a378-d49e9d819710_figure1.gif

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 flow diagram showing the process of study inclusion.

Table 1. Characteristics of included studies.

Author/yearN° ptsDiseaseMedian age (years)/PS 0-1 (%)Type of studyMedian follow up (months)Definition of OM
(n° of lesions)/%
Site of OMDe novo/metachronous (%)Treatment for OM (%)OS
(UVA or MVA)
PFS
(UVA or MVA)
Quality
Afshari/2019281CRC62/NRRetrospectiveNR1 (85)Various--MVA-5
Ai/20173245Esophageal66/NRRetrospectiveNR1-3 (NR)Various--MVA-5
Alt/2011887RCC62.5/85Retrospective33.62 (16.5)Various58/42S (14)MVA-8
Amikura/2017342CRCNR/NRRetrospective52.71-4 (75.7)Liver63/37S ± CT (100)MVAMVA8
Anraku/2003133Utherine56/NRRetrospective401 (58)Lung6/94S (100)MVA-7
Aparicio/2016282CRC80/100Phase 369.81-2 (77.8)Various-CT (100)MVAMVA-
Araujo/2015318CRC58/NRRetrospective601 (43)Liver-S (100) + CT (37)-MVA8
Armstrong/2007686Prostate68.5/88Retrospective701-2 (88)Various-CT (100)MVA-9
Atzpodien/2003425RCCNR/100Retrospective201-2 (82)Various0/100VariousMVA-7
Bachet/2019249CRC62.9/NRRetrospective28.71-3 (66)Liver79/21S ± CT (100)UVAMVA (DFS)6
Baldin/2021221CRC62/NRRetrospective44.51-3 (75.6)Liver74.2/25.8S ± perioperative tx (100)MVAMVA (TTR)7
Bartosch/2016130Utherine52/NRRetrospective481 (54)Various-VariousMVA-7
Bates/201196BreastNR/NRRetrospectiveNR1-2 (NR)Various-CT (100)MVAMVA (TTP)5
Beau-Faller/2019228NSCLCNR/42RetrospectiveNR1-2 (65)Various0/100TKI (100)MVAMVA5
Beppu/2014137CRC63/NRRetrospectiveNR1-5 (NR)Liver-CT ± S (100)MVA-5
Beuselink/2014200RCC59/85Retrospective671 (83)Various38/62Systemic tx (100)UVAUVA8
Bian/2016401MelanomaNR/83Retrospective351-4 (87)CNS-SBRT (100)MVA-7
Blanchette/2018154Breast56/NRRetrospective341 (55)Various25/75CT (100)MVA-7
Blazer III/2008305CRC57/NRRetrospective251 (32)Liver-CT + S (100)MVA-6
Bollig/2020283Head & neck59.8/NRRetrospectiveNR1 (18.7)Various-Various (100)MVA-5
Bolm/201539PancreaticNR/56Retrospective51 (56)Various-RT (100)MVA-6
Bossé/20203454
1061
RCC62/81
61/97
Retrospective
2-cohort
34
24.9
1 (19.5)
1 (17.2)
NR-TKI (100)MVA-6
Brandi/2013151CRC61.5/100Retrospective421 (61)Lung/Liver51/49S ± CT (100)-MVA8
Buhl/2018140Breast62/NRRetrospective6.21 (40)Various-CT (100)-MVA (TTP)5
Cai/2017143RCC60/NRRetrospective221 (72.7)Various-TKI (100)UVAUVA6
Cardona/20131004CRCNR/NRRetrospective591 (42)Liver-S (100)MVA-8
Catalano/2009255CRC67/92Retrospective451 (64)Various0/100CT (100)MVA-8
Chen/2010255CRCNR/NRRetrospective11.91 (67)Various100/0CT (67)MVA-6
Chen/20193981Various60.84/40.8Retrospective44.31 (16.5)Various-Various (100)MVA-7
Co/2019172Breast53/NRRetrospectiveNR1-3 (96)Various100/0Systemic tx
± S (100)
MVA-5
Comella/2005254CRCNR/97Pooled analysis of n = 2 trialsNR1 (55)Various54/46CT (100)MVAMVA5
Creasy 2018907CRC64/NRRetrospective1221 (52.7)Liver-S + CT (100)MVAMVA8
Cristobal/2014250CRC69.5/81RetrospectiveNR1-2 (90)Various65/35NRUVAMVA5
Dai/2020146RCC56.5/71.9Retrospective361 (56.8)Various45.9/54.1TKI (100)MVAMVA6
Daniel/2017109CRC58.4/NRRetrospectiveNR1-4 (46)Liver100/0S ± CT (100)MVA-5
de Baere/2015566Various62.7/NRRetrospective35.51-2 (78)Lung-RFA (100)MVAMVA7
de Geus-Oei/2006152CRC61.5/NRProspective171 (NR)Liver-VariousUVAUVA6
Dercle/2016251Various52/NRRetrospective10.51-2 (40)Various-ICIs (100)MVA-6
Ding/201785NSCLC66/75Retrospective9.81-3 (48)Various-TKI (94)MVAMVA6
Dudek/201933Sarcoma55/NRRetrospective371-3 (72.7)Lung36/64S (100)UVA-7
Efficace/2008742CRC62/92Retrospective analysisNR1 (40)Various-CT (100)MVA-5
Faron/2015810CRC63/83Pooled analysis of n = 4 trials331-2 (85)Various100/0CT ± SMVAMVA6
Fay/20184736RCC59.2/100Pooled analysis of n = 12 phase 2-3 trialsNR1 (NR)NR--MVA-6
Fujiwara/202045RCC62/82Retrospective26.41 (36)NR-Nivolumab (100)UVA-6
Furubayashi/201759RCC67/85RetrospectiveNR1-2 (86)Various-TKI (100)MVA-5
Ghiringhelli/2014409CRC65/59Retrospective321 (63)Various62/38S ± CT (100)MVA-6
Gobbini/201816702Breast61/NRCohort48.51-3 (92.6)Various28.5/71.5-MVA-8
Gu/2017184RCC54Retrospective23.31 (85)Various-VariousUVAMVA6
Gu/2018102CRC62/NRRetrospectiveNR1 (36)Liver0/100RFA ± CT (100)MVA-5
Gu/20201888BreastNR/NRRetrospectiveNR1 (NR)Various100/0VariousMVA-5
Han/201161SCLC65/71Phase 233.61-2 (NR)Various-CT (100)MVA-7
Hashimoto/2010466Gastric60/85RetrospectiveNR1-2 (NR)Various71.7/28.3CT (100)UVA-5
Hebbar/2015284CRC61.7/93Phase 3671 (48.9)Various/Liver 83.567.7/32.3S + CT (100)-MVA (DFS)8
Hernandez/2016522CRC64.5/NRRetrospective38.71 (65.7)Lung-CTMVAMVA6
Holliday/201734CRC56/NRRetrospective251-2 (100)Various100/0SCRTMVAMVA6
Huang/2020179CRC62/NRRetrospective27.61 (51.5)Lung-S (100)MVA-6
Iacono/2019162MelanomaNR/82Retrospective481-2 (66)Various-Systemic tx (100)MVA-7
Ikeda/2018116RCC66/NRRetrospective19.41 (66)Various-TKI (100)MVAMVA6
Ishiguro/2006111CRCNR/NRRetrospective431-3 (81)Liver100/0S (100)MVA-9
Ishihara/2017118RCCNR/NRRetrospectiveNR1 (NR)Various100/0SUVA-5
Ivars Rubio/2019263Breast59/81.4Retrospective44.91 (57.8)Various44.5/55.5OT (19.8)
CT (50.7)
CT + Bio (29.5)
UVAUVA7
Jiang/2015347NPC48/100RetrospectiveNR1 (28)Various100/0CT (57.9)
CT + RT (68.8)
RT (3.7)
MVA-5
Kadokura/2013208Gastric64/81.3Retrospective26.91 (69.7)Various-CTMVA-6
Kawamoto/202098SarcomaNR/NRRetrospectiveNR1-2 (43.9)Lung-Various-MVA (PMS)
Keizman/2014278RCC63/NRRetrospective551 (18)Various82/18TKI ± SUVAUVA8
Kemeny/2014169CRC55/NRRetrospective44.31-2 (47.3)Various66.8/33.2S + HAI + Systemic tx (100)-MVA (RFS)7
Kikawa/2019134Breast63.5/85.8RetrospectiveNR1-2 (73.9)Various24.6/75.4Everolimus (100)UVAUVA5
Kim/2008304Gastric54/73.3RetrospectiveNR1 (81.2)Various-CT (100)MVA-5
Kim/2017177RCC62/92.6Retrospective19.21-3 (NR)Various-TKI (100)MVAUVA6
Kimura/2019103Gastric67/NRRetrospectiveNR1-2 (89)Various-CT (100)MVA-5
Kinoshita/2015256Gastric64/NRRetrospective651-2 (82.8)Liver41.4/58.6S (100)
+ CT (32.8)
MVAUVA8
Kondoh/201850Gastric67/72RetrospectiveNR1-2 (74)Various-CT (100)UVA-5
Konopke/2009201CRC65/NRProspective311-3 (94)Liver34.8/65.2S (100)MVAMVA6
Kroger/2006187Breast45.5/NRPhase 3631-2 (41.5)Various29.5/70.5CT (100)MVAMVA7
Kwak/2007186RCC58/86.5Retrospective17.41 (60.2)Various39.8/60.2S ± ICIsMVAMVA6
Kwak/2007 (2)252RCCNR/61Retrospective171 (37)Various19/80ICIsMVAMVA6
Le Scodan/2009581Breast60.2/NRRerospective391 (58.9)Various100/0RT ± SMVA-7
Leal/2016513CRC64.1/NRRetrospective371 (61.6)Liver100/0SMVAMVA7
Lee/20092247Melanoma51/NRRetrospective22.51-2 (67.4)Various--MVA-6
Leone/20179143Breast61/NRRetrospective131 (36.2)Various100/0-MVA-6
Li/2019100Lung60/96.1Retrospective391-3 (13.7)Brain100/0TKI ± CTUVA-7
Lin/2018307CRC57.5/NRRetrospective31.71 (52.8)Liver66.4/33.6S (100)
± RFA (10.1)
± Systemic tx
MVA-7
Liou/2017266RCC61/NRRetrospective121 (43)Various-S (100)MVA-6
Lipton/2010102Breast55.4/100Retrospective341-2 (NR)Various-Trastuzumab (100) ± CT (88)MVAMVA (TTP)6
Liu/201052CRC70/NRRetrospective35.51 (58)Liver0/100S + CT (100)MVAMVA (DFS)6
Liu/2015981HCC52.5/NRProspective32.71 (70.3)Liver-± S (18.9)
± RFA (19.3)
± TACE (48.2)
-MVA (RTDS)7
Liu/2018216NSCLC57/NRRetrospective71-3 (NR)Brain-RT ± Systemic txMVA-6
Liu/2020125Osteosarcoma17/100RetrospectiveNR1-2 (72)Lung-CT ± S-MVA (PRS)5
Liu/2020182CRC59.5/NRRetrospective32.51-3 (NR)Liver65/35S ± CTMVAMVA (RFS)6
Lo/2017120Head & neckNR/NRRetrospective511-3 (68.3)LNs-S ± CT/RTMVAMVA (DFS)8
Lobbezoo/2015815Breast62.5/NRRetrospective37.11 (67)Various19/81Systemic tx (100)MVA-6
Lu/201667RCC58/95.5RetrospectiveNR1-4 (32.8)Bone-TKI (100)MVA-5
Luzzago/20191592Bladder68/NRRetrospectiveNR1 (44)Various-CT ± SMVA-5
Makiyama/2018444Gastric75/NRRetrospective28.71 (37.3)Various-CT (100)-MVA5
Margonis/2015334CRC50/NRRetrospective28.21-2 (NR)Liver54.8/45.2S (100)UVAMVA (RFS)6
Margonis/2017389CRC58.4/NRRetrospective20.81-2 (NR)Liver57.3/42.7S ± Ablation (18.5) ± CT (71.5)-MVA (DFS)6
Margonis/2019718CRC62.3/NRRetrospective30.41-3 (36.4)Liver51.2/48.8S ± Systemic txMVA-6
Mazzaferro/20091556HCC55/NRRetrospective531 (26)Liver-S (100)MVA-7
Mise/201098CRC62/NRRetrospective601-3 (68)Various0/100S (100)MVA-8
Miyamoto/201578CRC65/92Retrospective19.22 (37)Various--UVA-6
Moreau/2012115Melanoma59/NRRetrospective191-3 (64)LNs93/7S (100)MVAMVA (DMFS)6
Morino/2020232Biliary66/NRRetrospective12.61-3 (52)Various-± Locoregional
± Systemic tx
UVA-5
Narayan/2020357CRC60/NRProspective1271 (NR)Liver100/0S ± HAI-UVA (RFS)9
Nataraj/2016102Sarcoma18/60Retrospective231-3 (31)Lung31/69S ± CT (100)MVAMVA (EFS)6
Negri/2005135CRC60.5/82.2Case–control76.81 (60.7)Various100/0CT (100)MVA-8
Neofytou/2015140CRCNR/NRRetrospective331 (41.4)Liver71.4/28.6± S ± Systemic txUVAUVA6
Neron/202051Phyllodes56.4/95.9Retrospective62.11 (51)Various13.7/86.3± S (31.3)
± RT (31.9)
± CT (72.5)
UVA-7
Neuman/2010186Breast56/NRRetrospective521 (13)Various100/0CT (100)MVA-8
Nguyen/2012692Breast60/68.9Retrospective22.81-4 (33.6)Various-± Locoregional
± Systemic tx
MVA-6
Nie/2017209NPC45/81.3Retrospective16.61 (49.8)Various24.9/75.1CT (100)UVAUVA6
Niibe/201661NSCLCNR/100RetrospectiveNR1-2 (89)SNC18/82SBRT or SRS (100)MVA-5
Niikura/2012314Breast51.9/90.4Retrospective331 (23.8)Bone100/0BisphosphonatesMVAMVA6
Nojiri/201131CRC63.3/NRRetrospective621-2 (64.5)Lung3.2/96.8S (100)MVA-8
Paccagnella/2006324NSCLC62/93.7Phase 2-3191 (30.5)Various100/0CT (100)UVA-6
Park/2009317Breast48/93RetrospectiveNR1-2 (36)Various-VariousMVA-5
Park/2016221CRC62/NRProspective34.71 (73.3)Lung13.1/86.9S (100)
± CT (79.6)
UVAMVA (DFS)6
Park/2017134Biliary61/90Retrospective260-1 (90)Various-CT (100)MVAMVA6
Park/2019517NSCLC64/NRRetrospectiveNR1 (57)*Various100/0VariousMVA-5
Parkin/20135853CRC64/NRRetrospective201-3 (79)Liver37/50Surgery (100)MVA-5
Peng/2017150CRC58/NRRetrospective361 (NR)Liver67/33S ± CT (100)MVAMVA (RFS)6
Peng/2018140CRC55/NRRetrospective131-3 (79)Liver70/30MWA (100)-MVA6
Pons-Tostivint/20194276Breast60/NRRetrospective45.31-2 (77)Various100/0VariousMVA-7
Prasanna/2020513CRC63/NRRetrospectiveNR1 (NR)Various51/49S ± CTUVA-5
Prelaj/2019193Lung65/88Retrospective431-3 (NR)Various-IT (100)UVAMVA7
Ran/202049Breast50/NRRetrospective291-2 (NR)Various-Trastuzumab based (100)UVA-6
Rhu/2014262Breast47/NRRetrospective29.61-2 (84.7)Various100/0VariousMVA-6
Rhu/2017410CRC60/NRRetrospective341 (63)Liver-S (100)MVA-6
Richey/2011188RCC60.8/65Retrospective6.91 (36)Various100/0S + Systemic tx (100)MVA-6
Robelin/2019162Neuroendocrine61/90Retrospective561-2 (85)Various49/51VariousMVAUVA7
Ruzzo/201259CRCNR/100RetrospectiveNR1 (64)Various0/100CT (100)UVAUVA5
Sasaki/2016485CRC58.5//NRRetrospective311-3 (65)Liver57/43S/RFA (100)MVA-6
Sasaki/2017251CRC57/NRRetrospective30.31-3 (NR)Liver-S ± CT (100)MVA-6
Schmidt/2005321RCC51/NRRetrospective521-2 (60)Various-Citokines (100)UVA-7
Schneeweiss/2002118Breast44/NRRetrospective481-2 (86)Various-CT (100)UVAMVA7
Seremet/201985Melanoma57/91Retrospective211-2 (44.7)Various-ICIs (100)MVAUVA6
Sharma/201593RCC61/76Retrospective131 (60)Various100/0S ± Systemic tx (100)MVA-6
Shen L/2015505Head & neckNR/95Retrospective201 (18.8)Various100/0CT ± RT (100)MVA-6
Shen L/2015 (2)312Head & neck46/89.1Retrospective161-3 (62.2)Bone43.9/56.1VariousMVA-6
Shimizu/2019160CRC66/NRRetrospective641-3 (88)Lung18/83S (100)MVA-7
Shin/20161024NSCLC64/85.5Retrospective42.21 (14.8)*Various-Systemic tx (100)MVA-7
Shinoda/202048Liposarcoma43/NRRetrospective27.51 (52.1)Various-VariousUVA (DSS)5
Shirasawa/2019141SCLC70/62RetrospectiveNR1-5 (34.7)Various100/0CT (100)MVA-5
Shoushtari/2016215Sarcoma56/26Retrospective1751-2 (67)Various39/61CT (100)MVAUVA9
Silva/201961Various66.3/NRRetrospective13.581-5 (35)Spine-SBRT (100)-MVA (LC 1y)6
Smart/201966BTC76/55Retrospective211-2 (54)Liver-RT (100)MVAMVA6
Sorbye/2012342CRCNR/98.8Subgroup analysis of prospective randomNR1 (53)Liver34.5/64.5Various-UVA5
Souglakos/2009168CRC59/NRRetrospectiveNR1-2 (53)Various-CT (100)MVAMVA5
Sperduto/20161481NSCLCNR/69.2RetrospectiveNR1-4 (81)Brain-VariousMVA-5
Stang/2016113CRC70/NRRetrospective991-3 (77)Liver21/79RFA (100)
CT (95)
MVAMVA8
Stephens/201181Sarcoma43.5/NRRetrospective271-2 (33)Lung-S (100)MVA-7
Stremitzer/2015154CRC62/NRRetrospective341-2 (NR)Liver-S (100)MVAMVA6
Tablazon/2019837Prostate76/NRRetrospective261 (NR)Bone--MVA-7
Takagi/201971RCC66/99RetrospectiveNR1 (45)Various-TKI (100)MVA-5
Takahashi/201941NSCLC67/82Retrospective19.61 (57)Bone100/0Various (100)UVAUVA6
Tambo/202095NSCLC72/77.9Retrospective8.81-2 (80)NR-Pembrolizumab (100)MVAMVA5
Tarpgaard/2014566CRCNR/96Retrospective370-1 (29)Various-CT (100)MVAMVA6
Thiery-Vuillemin/2017224RCC67/82Retrospective18.31 (51)Various-Systemic tx
± S (100)
UVA-6
Van Cutsem/20041207CRC64/NRRetrospectiveNR1 (25)Various76/24CT (100)MVA-5
Wang/2016310Gastric58/100RetrospectiveNR1 (70.6)Various-VariousMVA-5
Wang/2017163CRC65/NRRetrospective371-2 (41)Liver82/18S + CT (100)MVAMVA6
Wang/2018321Gastric57/85Retrospecive320-1 (83)Various-CT (100)MVAMVA6
Wei/2005395CRC63/NRRetrospective311-3 (65)Liver51/49S (100)MVAMVA6
Weide/2012855Melanoma62/NRRetrospective251-2 (74.7)Various-VariousMVA-6
Wong/2019483Breast49/NRretrospective661 (88)Various100/0Systemic tx (100)MVA-7
Xie/2018332CRC58/NRRetrospective27.71 (65.2)Various72/18VariousMVA-6
Yamamoto/201851RCC65/80RetrospectiveNR1 (45)Various-TKI (100)UVAUVA5
Yamashita/201774CRC59/NRRetrospective251 (74)Liver-RFA/MWA
+ CT (100)
MVAMVA6
Yin/201999Cervix53/51.6Retrospective11.61-3 (37.3)Various--MVAMVA6
Yoon/201052HCC49/NRRetrospective16.31 (75)Lung-S (100)MVA-6
You/2016325RCCNR/NRRetrospectiveNR1 (37)Various55/45S ± CTMVAMVA5
Zhang/2019287RCC56/NRRetrospective281 (53)Various-S (100)MVAMVA6
Zhang/2020160Prostate68/NRRetrospective47.21-4 (39.4)Bone-RT + OT (100)UVA-7
Zhao/2017289CRC57/NRRetrospective341 (51)Liver66/34S (100)MVAMVA6

* M1b single extratoracic organ; CNS, central nervous system; CRC, colorectal cancer; CT, chemotherapy; DMFS, distant metastasis–free survival; DSS, disease-specific survival; EFS, event-free survival; HAI, hepatic artery infusion; HCC, hepatocellular carcinoma; ICIs, immune checkpoint inhibitors; LNs, lymph nodes; MVA, multivariate analysis; MWA, microwave ablation; NPC, nasopharyngeal carcinoma; NSCLC, non-small-cell lung cancer; OM, oligometastatic disease; OS, overall survival; OT, ormonotherapy; PFS, progression-free survival; PMS, post-metastasis survival; PRS, post-relapse survival; PS, performance status; RCC, renal cell carcinoma; RFA radiofrequency ablation; RFS, relapse-free survival; RTDS, recurrence to death survival; S, surgery; RT, radiotherapy; SBRT, stereotactic body radiotherapy; SCLC, small-cell lung cancer; SRS, stereotactic radiosurgery; TACE, transarterial chemoembolization; TKI, tyrosine kinase inhibitor; TTP, time to progression; TTR, time to recurrence; tx, therapy; UVA, univariate analysis.

Progression-free survival was better in patients with OM disease (HR = 0.62, 95% CI 0.57–0.68; P < .01; n = 69 studies; Figure 2). Additionally, in the OS analysis, OM cancers were associated with a better OS (HR = 0.65, 95% CI 0.62–0.68; P < .01; n = 161 studies; Figure 3). Results were significant for all analyzed disease subgroups except biliary tract cancer and cervical cancer (only three studies included). In colorectal (CRC), breast, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC), which constituted the more representative series, the reduction in the risk of death for OM patients were 35, 38, 30 and 42%, respectively (Figure 3). Timing of onset did not influence the risk of death. Most studies reported OS analysis for up to three metastases (152 out of 161 studies). After exclusion of eight studies that reported outcomes for up to five metastases the final results remained unchanged (HR = 0.64, 95%CI 0.61-0.67; P < .01). No cut-off was associated with a better outcome (1 vs 2 vs 1-2 vs 1-3 metastases).

f8157814-93df-4685-a378-d49e9d819710_figure2.gif

Figure 2. Progression-free survival of oligo- compared to non-oligometastatic cancers.

f8157814-93df-4685-a378-d49e9d819710_figure3.gif

Figure 3. Overall survival of oligo- compared to non-oligometastatic cancers.

Risk of bias through Begg's funnel plot was not significant for the OS analysis. Conversely, Egger's test showed evidence of bias (P < .01) (Figure 4). Trim and Fill analysis incorporated 29 missing studies. The overall effect measure (95% CI) based on this analysis was 0.7 (0.67-0.73), which became slightly weaker compared to the originally reported overall effect measure. Compared with cancers with more than three to five metastases, high-certainty evidence indicates OM tumors are associated with better prognosis in particular for CRC, breast, NSCLC and RCC.

f8157814-93df-4685-a378-d49e9d819710_figure4.gif

Figure 4. Funnel plot of publication bias for overall survival analysis showing standard error by log hazard ratio.

Discussion

The definition of oligometastatic refers to malignancies with a limited metastatic spread which may be amenable of radical treatment for both primary and each distant site, and that generally have a better prognosis compared to polymetastatic cancers. A very recently published paper clearly explains the timely clonal evolution of somatic mutations and consequently the metastatic process of many cancer types.11 It may be hypothesized that OM cancer is associated with a more indolent spread and therefore may represent a less fatal disease. With the expansion of the oncological armamentarium, many efforts have been made over the years to improve outcomes of patients with minimal metastatic burden.

We have performed the most exhaustive systematic review of the literature to quantify the prognostic value of OM stage in various cancers. Overall, OM cancer patients have a risk of death and progression that is a third less than the polymetastatic counterpart. The OM state is frequently calculated as an independent favorable prognostic variable, which means that these patients do well independent from other clinical-pathological characteristics. The effect size was calculated from 173 studies including more than 100,000 patients. The final results were similar in all the most frequent histologies including CRC, breast cancer, NSCLC, RCC and sarcoma with inferior survival in OM gastric, melanoma and head and neck cancers.

There is evidence from randomized clinical trials12-14 that ablative therapies improve survival in patients with OM cancer. For example, in some cancers small randomized studies12-20 already provide evidence of survival improvement in patients that received both systemic and local therapies compared to those that received systemic therapies alone. As a matter of fact, resection of colorectal cancer liver metastases nowadays represents an essential curative option and a primary endpoint in multiple clinical trails.12 Furthermore, Gomez et al.13 found that in OM NSCLCs, adding local consolidative therapy to active oligometastases and to primary disease may improve OS from 17 to 41 months. Also, in RCC the treatment of indolent lung metastases may permit delaying the start of systemic treatment and obtain an excellent control.14 A large burden of evidence now supports local therapy for minimal oligoprogressive cancers treated with targeted therapies or immunotherapy. Here, metastases-directed therapy could delay the switch of systematic therapy by radical local treatment of all progressive metastatic sites.15,16 With the advent of immunotherapy, the combination of immune check point inhibitors and radiotherapy to single OM lesions may facilitate a potentiation of the immune response, increasing the chances of achieving an abscopal effect. This term describes an event in which focalized radiotherapy discharge systemic anti-tumoral action that can result in distant responses.17 For example, in lung cancer the combination has a good safety profile and achieves high rates of local control and greater chances of obtaining abscopal responses than radiotherapy alone, with a relevant impact on outcome.18 Oligometastatic cancers can also regarded as extended locoregional disease if, after proper conversion therapy, all sites of metastases and primary tumor may be radically resected with curative purposes. Such a strategy has been employed in largely incurable cancers ad gastric and pancreatic carcinomas.19,20

This meta-analysis has several limitations. First, our review does not evaluate the absolute benefit of any local treatment and the prognosis and management of oligoprogressive disease or down staged polymetastases to an OM state. Second, the literature search covered a large lifetime span and may include older series where radiological evaluation did not include more advanced modalities that can now increase the accuracy of oligometastases detection. Finally, the optimal number of lesions defining the OM state cannot be defined in this paper.

A consensus paper of EORTC and ESTRO societies attempted to provide definitions of various OM conditions either naïve or attained after therapy and either synchronous or metachronous.21

Some large, randomized studies have included local therapies for OM cancers. An NRG Oncology randomized phase II/III trial study compares therapy with stereotactic radiosurgery and/or surgery with standard of care therapy alone in treating patients with breast cancer that has one or two locations in the body (limited metastatic) that are previously untreated. The PREST study will assess the efficacy of ablative radiotherapy (stereotactic body radiotherapy applied to all oligometastases) administered to all tumor sites (metastases and prostate if applicable), in oligometastatic hormone-sensitive prostate cancer patients. Finally, an ECOG-ACRIn phase III study compared standard chemotherapy to consolidative radiotherapy in patients with oligometastatic HER2 negative esophageal and gastric adenocarcinoma (https://clinicaltrials.gov/ct2/show/NCT02364557; https://clinicaltrials.gov/ct2/show/NCT04115007; https://clinicaltrials.gov/ct2/show/NCT04248452).

Conclusions

In conclusion, this meta-analysis tried to quantify the prognosis associated with OM compared to cancers with more extensive diffusion. Based on our findings, we suggest that every metastatic patient should be accurately evaluated for the number of distant sites of disease, and a treatment strategy that involves both the primary and the metastases should be carefully considered. Also, we propose that these patients should be stratified when included in clinical trials.

Data availability

Extended data

Mendeley Data: Extended data for ‘Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies’.

http://dx.doi.org/10.17632/8kycvdnp6v.1.10

This project contains the following extended data:

  • Supplementary Table 1: List of included studies.

Reporting guidelines

Mendeley Data: PRISMA checklist for ‘Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies’.

http://dx.doi.org/10.17632/8kycvdnp6v.1.10

Data are available under the terms of the Creative Commons Attribution 4.0 license (CC-BY 4.0).

Comments on this article Comments (0)

Version 4
VERSION 4 PUBLISHED 27 May 2021
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Petrelli F, Ghidini A, Ghidini M et al. Better survival of patients with oligo- compared with polymetastatic cancers:  a systematic review and meta-analysis of 173 studies [version 1; peer review: 1 approved with reservations]. F1000Research 2021, 10:423 (https://doi.org/10.12688/f1000research.52546.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 27 May 2021
Views
33
Cite
Reviewer Report 30 Jun 2021
Luca G. Campana, Department of Surgery, Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, UK;  Department of Surgery, Manchester University NHS Foundation Trust, Manchester, UK 
Approved with Reservations
VIEWS 33
The authors of this systematic review and meta-analysis assessed the influence of oligometastatic disease status on OS and PFS in adult patients with solid tumours. To do this, they carried out an extensive literature review including all types of studies ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Campana LG. Reviewer Report For: Better survival of patients with oligo- compared with polymetastatic cancers:  a systematic review and meta-analysis of 173 studies [version 1; peer review: 1 approved with reservations]. F1000Research 2021, 10:423 (https://doi.org/10.5256/f1000research.55843.r87329)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 09 Jul 2021
    Fausto Petrelli, Oncology Unit, asst bergamo ovest, Treviglio (BG), Italy
    09 Jul 2021
    Author Response
    Reviewer 1: Luca Campana

    The authors of this systematic review and meta-analysis assessed the influence of oligometastatic disease status on OS and PFS in adult patients with solid tumours. ... Continue reading
  • Author Response 25 Aug 2021
    Fausto Petrelli, Oncology Unit, asst bergamo ovest, Treviglio (BG), Italy
    25 Aug 2021
    Author Response
    • We have improved the Introduction and criteria for search.
       
    • We have arranged in the Discussion section a specific discussion about particular settings of patients analysed
    ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 09 Jul 2021
    Fausto Petrelli, Oncology Unit, asst bergamo ovest, Treviglio (BG), Italy
    09 Jul 2021
    Author Response
    Reviewer 1: Luca Campana

    The authors of this systematic review and meta-analysis assessed the influence of oligometastatic disease status on OS and PFS in adult patients with solid tumours. ... Continue reading
  • Author Response 25 Aug 2021
    Fausto Petrelli, Oncology Unit, asst bergamo ovest, Treviglio (BG), Italy
    25 Aug 2021
    Author Response
    • We have improved the Introduction and criteria for search.
       
    • We have arranged in the Discussion section a specific discussion about particular settings of patients analysed
    ... Continue reading

Comments on this article Comments (0)

Version 4
VERSION 4 PUBLISHED 27 May 2021
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.